Julia K. Rotow, MD, outlines some major areas where advances are needed in the management of patients with early-stage non–small cell lung cancer (NSCLC). First, she anticipates that immunotherapies and targeted therapies available in the metastatic setting will become available as personalized therapy for patients in the early-stage setting.
Additionally, Dr Rotow looks at tools such as cell-free DNA technology that are starting to show some ability to better assess treatment response and disease progression in patients with early-stage NSCLC. She looks to a future where more dynamic options are available in the neoadjuvant setting for patients with early-stage NSCLC to better tailor therapy and improve long-term outcomes.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Advances in Treatment Options for Early-Stage NSCLC - Medscape - Sep 07, 2022.